Trials / Conditions / Recurrent Salivary Gland Carcinoma

Recurrent Salivary Gland Carcinoma

14 registered clinical trials studyying Recurrent Salivary Gland Carcinoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers NCT05669664	National Cancer Institute (NCI)	Phase 2
Recruiting	Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus NCT05408845	NRG Oncology	Phase 2
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer NCT04895735	Mayo Clinic	Phase 2
Unknown	Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary NCT03146650	Northwestern University	Phase 2
Completed	Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivar NCT02538510	University of Washington	Phase 1 / Phase 2
Completed	Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma NCT01604772	National Cancer Institute (NCI)	Phase 2
Completed	Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer NCT01254617	National Cancer Institute (NCI)	Phase 1
Completed	Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who D NCT01256385	National Cancer Institute (NCI)	Phase 2
Completed	Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma NCT01175980	National Cancer Institute (NCI)	Phase 2
Completed	Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer NCT00954226	M.D. Anderson Cancer Center	Phase 1
Completed	Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors NCT00859937	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squam NCT00588770	National Cancer Institute (NCI)	Phase 3
Completed	Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer NCT00458978	National Cancer Institute (NCI)	Phase 2